


# RNAscope® SpotStudio™ Software for Quantitative Image Analysis

## It Works the Way You Work

RNAscope® SpotStudio™ Software integrates seamlessly into your work environment, ensuring ease of use without sacrificing reliability. RNAscope® SpotStudio™ software is designed for pathologists with no prior training in image analysis. This intuitive software allows you to load any image\*, select a region of interest, define settings and run analysis, followed by a quality control review before results are exported.


RNAscope® SpotStudio™ - empowering pathologists.



\*You can analyze images from whole slide scanners, microscopic results.

## An Easy-to-Use Tool for Quantitative Biomarker Analysis

Software provides a workflow with a focused approach on getting to the answer quickly, easily and accurately. Get quantitative results to complement your visual result and standardize image analysis in your lab.




Get statistical results with complete information of cell-count/region, and number of spots/cell.

## A Complete Solution: RNAscope® from Assay to Answer

Quantitative RNA in situ hybridization analysis is now possible with single molecule sensitivity and digital nature of RNAscope® Assay Technology. There is a need to identify cells of interest for quantitative analysis and further enable interpretation of molecular markers in histopathological context. Testing results have indicated results obtained with RNAscope® SpotStudio™ are comparable to careful manual annotations by pathologists.

\*\*Wang et al. Automated Quantitative RNA in Situ Hybridization for Resolution of Equivocal and Heterogeneous ERBB2 (HER2) Status in Invasive Breast Carcinoma. *The Journal of Molecular Diagnostics*. 2013 March 15. 15(2):210-9.



## Customer Testimonial

"RNAscope® SpotStudio™ Software is very easy to use. I especially like the ability to interact with the image in the result section – to connect the quantitative result to the image of the cell in question is invaluable!!!"

-- Olga Shebanova,  
Research Investigator, Novartis